Renal Disease Market Segmentation

A comprehensive segmental analysis of the Global Renal Disease Market is available in MRFR’s report. The segment analysis covers disease types, treatment types, and end uses.

By disease type, the market has been segmented into end-stage renal diseases (ESRD) and chronic kidney disease. The chronic kidney disease segment holds a significant share of the market in terms of revenue. In 2017, the segment commanded more than USD 60,200 Mn and is expected to highly attractive during the forecast period. By treatment type, the market has been segmented into kidney transplantation, medication, and dialysis.  Based on end user, the market has been segmented into research and academic institutes, hospitals & clinics, and dialysis centers.

Renal Disease Market Players

  • Abbott (US)
  • Amgen Inc (US)
  • AstraZeneca (US)
  • Bristol-Myers Squibb Company (US)
  • Hoffmann- La Roche Ltd (Switzerland)
  • Fresenius Medical Care AG & Co., Ltd (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • Sanofi SA (France) and
  • Teva Pharmaceutical Industries Ltd (Israel)

Renal Disease Market Overview

Renal disease also known as kidney diseases that affects the functioning of kidneys. According to The Renal Disease market is accruing and expected to gain further prominence over the forecast period mainly due to the growing prevalence of chronic Renal Disease, technological advancements and availability of effective treatments.   According to a recent study report published by the Market Research Future, The global market of Renal Disease is projected to accrue at a rapid pace during the forecast period .The Market is forecasted to accrue USD 14291.2 Million with a striking CAGR of 11.20% during the forecast period of 2022-2030. Most Renal diseases attack the nephrons. This damage may leave kidneys unable to remove wastes. Causes can include genetic problems, injuries, or medicines. Diabetics and high blood pressure patients have a higher risk of kidney disease.  Chronic Renal disease damages the nephrons slowly over several years.

Renal disease also known as kidney diseases that affects the functioning of kidneys. According to National Kidney Foundation, Inc., 10% of world’s population is suffering from chronic kidney diseases. Global Renal disease Market is growing moderately. The growing prevalence of renal diseases is leading the market growth. Increasing R&D activities and clinical trials are major driving forces of the market. Increasing acquaintance and awareness among the patients, growing healthcare sector, government initiatives and new product launches are key factors for the global renal disease market. With the number of kidney failure patients expected to continue to rise in the future, healthcare providers are seeking new ways to expand treatment options, improve outcomes, and reduce the chronic health conditions that contribute to the potentially deadly disease.

Most Renal diseases attack the nephrons. This damage may leave kidneys unable to remove wastes. Causes can include genetic problems, injuries, or medicines. Diabetics and high blood pressure patients have a higher risk of kidney disease.  Chronic Renal disease damages the nephrons slowly over several years. A recent study also emphasises on Air pollution that could harm your kidneys. People with Renal Diseases are at increased risk of developing a life-threatening abnormal heart rhythm, a new report suggests. Chronic Renal disease can as much as double a patient's risk of atrial fibrillation, a quivering or irregular heartbeat that can lead to stroke or heart failure. The risk of atrial fibrillation increases as kidney function declines.

 

Renal Disease Market Regional Analysis

Considering the global scenario of the market, North America is believed to be the largest market for global renal disease. Moreover the European market is the second largest market for global renal disease and Western Europe region is the dominating the market in Europe. On the other hand, Asia-Pacific (APAC) is expected to grow at significant rate in the global renal disease market during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of disease and treatment.

A vague statistic indicates that 30 million American adults are likely to have chronic kidney disease and most aren't aware of it.  1 in 3 American adults are at risk for chronic kidney disease.  Risk factors for kidney disease include diabetes, high blood pressure, heart disease, obesity and family history of kidney failure. People of African American, Hispanic, Native American, Asian or Pacific Islander descent are at increased risk for developing the disease.  African Americans are 3 times more likely than Whites, and Hispanics are nearly 1.5 times more likely than non-Hispanics to develop end stage renal disease.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/renal-disease-market-3167

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com